Employees: 376
Size SI-BONE (SIBN) is a United States Health Care company (Medical Specialties) with a market value of $1.06B, the 2193rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $23.54 on 18 Nov 2026.
Performance Over six months the shares gained 58.8%, against -8.9% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 14.0% over the last twelve months (peer median +10.0%); the operating margin is -7.6% (peer median 17.4%).
Valuation It trades at 4.3× enterprise value to sales against a peer median of 4.0× (10th most expensive of 20).
Capital Return on invested capital runs 24.4 points below its cost of capital (8.2% WACC).
Short interest Short interest is 10.0% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $221M | $201M | $167M | $139M | $106M |
| Revenue growth | — | +20% | +20% | +31% | — |
| Gross profit | $175M | $160M | $132M | $109M | $90.7M |
| EBITDA | -$10.1M | -$16.6M | -$30.9M | -$41.5M | -$56.2M |
| Net income | -$13.7M | -$18.9M | -$30.9M | -$43.3M | -$61.3M |
| Free cash flow | -$4.19M | -$9.09M | -$22.9M | -$26.5M | -$51.2M |
| Capital expenditure | $10.3M | $8.41M | $10.5M | $7.80M | $9.51M |
| Total debt | $42.8M | $36.7M | $37.5M | $39.0M | $39.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SIBN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.6% | -6.0% | 3rd highest of 21 |
| 6-month return | +58.8% | -8.9% | 2nd highest of 20 |
| Distance from 52-week high | -9.2% | -29.4% | highest of 21 |
| Revenue growth (TTM) | +14.0% | +10.0% | 7th highest of 19 |
| Operating margin | -7.6% | 17.4% | 4th lowest of 20 |
| EV / Sales | 4.3× | 4.0× | 10th most expensive of 20 |
| ROIC minus cost of capital | -24.4 pp | +3.2 pp | 2nd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | 4.3× | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | 85.0× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 6.3× | 8.8% | +8.8% |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 11.1× | 18.5% | +21.5% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 1.7× | 5.9% | +3.6% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 4.0× | -9.2% | +34.5% |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | 4.7× | n/a | n/a |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 1.9× | n/a | n/a |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | 2.1× | 57.7% | +40.6% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 2.7× | 7.7% | +12.1% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | 3.0× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | 11.1× | 50.8% | +8.6% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 0.9× | -4.0% | +3.5% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 4.7× | 4.9% | +10.4% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 2.5× | 6.9% | -2.9% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 5.8× | 1.7% | +9.9% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | 8.3× | n/a | n/a |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 4.7× | 11.3% | -3.5% |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 3.1× | 10.7% | +12.9% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 3.9× | 3.3% | +13.9% |